Mumbai: Glenmark Life Sciences (GLS), wholly-owned arm of Glenmark Pharmaceuticals, has filed preliminary papers for an initial public offer with market regulator Securities and Exchange Board of India (SEBI).

GLS has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) for an initial public offer, according to a regulatory filing.

The offer comprises fresh issue of up to Rs 1,160 crore and an offer for sale of up to 73,05,245 equity shares of Rs 2 each of Glenmark Life Sciences Ltd, by Glenmark Pharmaceuticals Ltd, the filing said.

The board of directors of Glenmark Pharmaceuticals Ltd during its meeting on April 16 approved the offer for sale of up to 73,05,245 equity shares of Rs 2 apiece as part of the IPO.

The IPO will be subject to market conditions, receipt of applicable approvals and other considerations, the filing said.

You may also like to read: Glenmark Pharma to use $40 mn loan to refinance existing debt and capex

About the author

TEAMIU

Leave a Comment